- Home
- NRIX vs GOF Comparison
NRIX vs GOF Comparison
Compare NRIX & GOF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NRIX | GOF |
|---|---|---|
| Founded | 2009 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.3B |
| IPO Year | 2020 | 2006 |
Fundamental Metrics
Financial Performance| Metric | NRIX | GOF |
|---|---|---|
| Price | $25.37 | $8.63 |
| Analyst Decision | Buy | |
| Analyst Count | 14 | 0 |
| Target Price | ★ $34.50 | N/A |
| AVG Volume (30 Days) | 1.9M | ★ 2.2M |
| Earning Date | 10-12-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.26 | N/A |
| Revenue | ★ $76,987,000.00 | N/A |
| Revenue This Year | $786.93 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $7.82 | ★ N/A |
| Revenue Growth | ★ 99.31 | N/A |
| 52 Week Low | $11.19 | $8.40 |
| 52 Week High | $28.23 | $13.98 |
Technical Indicators
Market Signals| Indicator | NRIX | GOF |
|---|---|---|
| Relative Strength Index (RSI) | 58.20 | 43.90 |
| Support Level | $24.61 | $8.41 |
| Resistance Level | $28.23 | $9.00 |
| Average True Range (ATR) | 1.21 | 0.17 |
| MACD | 0.39 | 0.03 |
| Stochastic Oscillator | 81.41 | 36.44 |
Price Performance
Historical ComparisonAbout NRIX Nurix Therapeutics Inc.
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.
About GOF Guggenheim Strategic Opportunities Fund of Beneficial Interest
Guggenheim Strategic Opportunities Fund is a diversified, closed-end management investment company. The Fund's investment objective is to maximize total return through a combination of current income and capital appreciation. It has single operating segment. Its products are Mutual Funds, Wealth Management SMAS, Institutional SMAS, ETFS, UITS, UCITS, CIT, Closed-End Funds, Private Funds, Rydex Funds, and Variable Insurance funds.